PT  - JOURNAL ARTICLE
AU  - Paradiso, Angelo Virgilio
AU  - Summa, SimonaDe
AU  - Silvestris, Nicola
AU  - Tommasi, Stefania
AU  - Tufaro, Antonio
AU  - De Palma, Giuseppe
AU  - Larocca, Angela Maria Vittoria
AU  - Chironna, Maria
AU  - D’Addabbo, Vincenzo
AU  - Raffaele, Donata
AU  - Cafagna, Vito
AU  - Garrisi, Vito
TI  - RAPID SEROLOGICAL TESTS HAVE A ROLE IN ASYMPTOMATIC HEALTH WORKERS COVID-19 SCREENING
AID  - 10.1101/2020.04.15.20057786
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.04.15.20057786
4099  - http://medrxiv.org/content/early/2020/04/17/2020.04.15.20057786.short
4100  - http://medrxiv.org/content/early/2020/04/17/2020.04.15.20057786.full
AB  - Health workers are at high risk for SARS-CoV-2 infection and, if asymptomatic, for transmitting the virus on to fragile cancer patients. We screened 525 health workers of our Cancer Institute with rapid serological test Viva-Diag analyzingCOVID-19 associated-IgG/IgM. Six subjects (1,1%) resulted with Viva-Diag test not-negative for IgM. All 6 cases had RT-PCR SARS-CoV-2 test negative; repeating analysis ofIgG/IgM expression by CLIA assay also, 2 cases resulted IgM positive and 1 case IgG/IgM positive. This latter subject reported a contact with an infected SARS-CoV-2 person, a month earlier.In conclusion our study seems to suggest: a) a different analytical sensitivity inIgG/IgM evaluation for Viva-Diag and CLIA assays needing to be further determined; b) the ability of Viva-Diagrapid COVID-19 test to evidence health workers positive for Immunoglobulins expression. Discordant results of rapid serological tests with respect to RT-PCR stress the different clinical meaning the two assays can have, question clearly referring to further studies to optimize the utilization of rapid serological test in asymptomatic subjects at high risk for infection.Competing Interest StatementThe authors have declared no competing interest.Funding StatementItalian Ministry of Health (Ricerca Corrente 2020)Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are presented in the paper